CAMBRIDGE, Mass., March 16 /PRNewswire/ -- VisEn Medical today announced that Jeffrey D. Peterson, Ph.D. has joined the company as Director of Applied Biology. He will direct the development of new and advanced applications for VisEn’s proprietary Fluorescence Molecular Tomography (FMT) system and optical imaging probe portfolio. He will also spearhead key evaluation and optimization programs for VisEn’s expanding probe and system product offerings going forward. An expert in autoimmune and inflammatory diseases, Dr. Peterson brings over 20 years of academic and industrial experience to VisEn.
“We are proud to announce the addition of Jeff Peterson to the scientific team at VisEn Medical,” said Kirtland G. Poss, President and CEO. “His expertise in disease biology, animal models and drug development will help us to expand the applications of our technology and support its use by our growing family of customers,” he added.
Prior to joining VisEn, Dr. Peterson served as a Group Leader in the Pharmacology Department of Abbott Bioresearch Center (Worcester, MA), where he managed the Arthritis Group as well as provided Pharmacology and Biology leadership of key drug discovery projects. Dr. Peterson began his career as a Neuroscientist/Immunologist at Northwestern University Medical School (Chicago, IL) and the Barbara Davis Center for Childhood Diabetes (Denver, CO). He spent several years establishing expertise in mouse models of basic immune function, autoimmune and viral-induced multiple sclerosis, autoimmune diabetes, and alcohol-induced immunomodulation. Subsequently, Dr. Peterson joined Boehringer Ingelheim (Ridgefield, CT) to run the In Vivo Proof of Concept laboratory. He later built and led the Pharmacology Group at CuraGen Corporation (Branford, CT), a genomics and biopharmaceutical company, establishing a portfolio of experience in a wide variety of indications including autoimmune disease, cancer, radiotherapy-induced mucositis, kidney disease, and stroke.
About VisEn Medical
Founded in 2000 based on imaging technologies developed at the Center for Molecular Imaging Research at the Massachusetts General Hospital, VisEn Medical is developing today’s leading optical molecular imaging technology platforms. The Company’s products enable applied imaging of biologic and molecular processes in vivo, and its products are targeted to the imaging of central disease states including oncology, bone growth, cardiovascular disease and inflammation. VisEn is headquartered in Woburn, Massachusetts. For further information please visit http://www.visenmedical.com.
Contact: Kirtland G. Poss, President and CEO
VisEn Medical, Inc. 781-932-6875 x301
VisEn Medical
CONTACT: Kirtland G. Poss, President and CEO of VisEn Medical, Inc.,+1-781-932-6875 ext. 301
Web site: http://www.visenmedical.com/
